Skip to main content
logo
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.885
-0.055 (-2.84%)
Oct 8, 2026, 12:18 PM EDT - Market open

Inhibikase Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.260.123.1
Revenue Growth
---111.03%-96.02%343.92%
Gross Profit
----13.36-11.91-8.26
Operating Income
-66.22-45.95-28.59-20.09-18.13-14.77
Net Income
-60.64-48.26-27.52-19.03-18.05-14.79
Earnings Per Share
-0.43-0.49-1.16-3.16-4.28-4.87
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
159.02178.7697.5413.2523.0540.75
Total Debt
--0.110.620.350.25
Net Cash (Debt)
159.02178.7697.4312.6322.740.5
Net Cash Growth
81.47%83.47%671.44%-44.36%-43.95%197.05%
Net Cash Per Share
1.131.824.112.105.3713.35

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-42.61-27.79-19.15-18.09-17.35-14.3
Capital Expenditures
--0.01--0.01-0.24-
Free Cash Flow
-42.61-27.8-19.15-18.1-17.59-14.3
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------266.35%
Operating Margin
----7711.98%-14686.17%-476.23%
Pretax Margin
----7304.73%-14625.85%-476.88%
Profit Margin
----7304.73%-14625.86%-476.88%
FCF Margin
----6947.87%-14253.37%-461.10%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---30.10102.1811.93